Heavy-chain CDR3-engineered B cells facilitate in  vivo evaluation of HIV-1 vaccine candidates

V2-glycan/apex broadly neutralizing antibodies (bnAbs) recognize a closed quaternary structure of the HIV-1 envelope glycoprotein. He, Ou et  al. introduced HCDR3 regions of neutralizing antibodies targeting this epitope into a diverse repertoire of murine B cell receptors (BCRs). Upon vaccination, these edited B cells affinity matured and generated potent neutralizing sera, highlighting the potential of an HCDR3-focused vaccine approac h.

Source: Immunity - August 1, 2023 Category: Allergy & Immunology Authors: Wenhui He, Tianling Ou, Nickolas Skamangas, Charles C. Bailey, Naomi Bronkema, Yan Guo, Yiming Yin, Valerie Kobzarenko, Xia Zhang, Andi Pan, Xin Liu, Jinge Xu, Lizhou Zhang, Ava E. Allwardt, Debasis Mitra, Brian Quinlan, Rogier W. Sanders, Hyeryun Choe, M Tags: Article Source Type: research